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Abstract DNA methylation and histone H4 acetylation play a
role in gene regulation by modulating the structure of the
chromatin. Recently, these two epigenetic modifications have
dynamically and physically been linked. Evidence suggests that
both modifications are involved in regulating imprinted genes ^ a
subset of genes whose expression depends on their parental
origin. Using immunoprecipitation assays, we investigate the
relationship between DNA methylation, histone H4 acetylation
and gene expression in the well-characterised imprinted Igf2-H19
domain on mouse chromosome 7. A systematic regional analysis
of the acetylation status of the domain shows that parental-
specific differences in acetylation of the core histone H4 are
present in the promoter regions of both Igf2 and H19 genes, with
the expressed alleles being more acetylated than the silent alleles.
A correlation between DNA methylation, histone hypoacetyla-
tion and gene repression is evident only at the promoter region of
the H19 gene. Treatment with trichostatin A, a specific inhibitor
of histone deacetylase, reduces the expression of the active
maternal H19 allele and this can be correlated with regional
changes in acetylation within the upstream regulatory domain.
The data suggest that histone H4 acetylation and DNA
methylation have distinct functions on the maternal and paternal
Igf2-H19 domains. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
DNA methylation and histone acetylation alter the chro-
matin structure to repress or activate transcription. Recent
studies have suggested that DNA methylation and histone
deacetylation may operate along a common mechanistic path-
way to repress transcription[1^3]. In mammals, these two epi-
genetic modi¢cations appear to play a role in genomic im-
printing, a mechanism of gene regulation whereby the two
alleles of a gene are expressed di¡erentially according to their
parental origin [4^6].
Igf2 and H19 are closely adjacent, reciprocally imprinted
genes, localised on human chromosome 11 and mouse chro-
mosome 7. Igf2 encodes a foetal growth factor and is nor-
mally expressed from the paternal allele, while H19 transcrip-
tion is exclusively from the maternal allele, producing a non-
coding RNA of unknown function. The strongest evidence for
the involvement of CpG methylation in Igf2 and H19 regu-
lation comes from studies in mice de¢cient for a DNA meth-
yltransferase gene, Dnmt-1. Indeed, these mutant embryos
could not express Igf2 but expressed H19 from both parental
alleles [7]. In addition, sites of regional and parental-speci¢c
methylation have been mapped [6] (Fig. 1), with the paternal
H19 allele being heavily methylated compared to the active
maternal H19 allele. The involvement of chromatin structure
is evident from the identi¢cation of allele-speci¢c di¡erences
in nuclease accessibility [8,9] (Fig. 1) and replication timing in
imprinted domains [10,11]. Recent work indicates that histone
acetylation, one of the epigenetic modi¢cations able to a¡ect
the chromatin structure, is involved in Igf2 and H19 regula-
tion. Parental-speci¢c acetylation has been identi¢ed in the
coding region of the H19 gene and treatment with speci¢c
inhibitor histone deacetylase induced changes in the expres-
sion of Igf2 and H19 [12^14]. However, the precise epigenetic
changes responsible for this were not determined.
Molecular and genetic analyses have shown that two re-
gions play key roles in allele-speci¢c expression of Igf2 and
H19 : a di¡erentially methylated region (DMR) upstream of
H19 [15^17] and a set of tissues-speci¢c enhancers down-
stream of H19 [18,19]. The enhancers speci¢cally contribute
to the activation of Igf2 on the paternal chromosome and to
the activation of H19 on the maternal chromosome. The in-
teractions between the enhancers and the genes are regulated
by the DMR. When this region is methylated, the H19 gene is
inactivated. Reciprocally, when this region is unmethylated,
the Igf2 gene is insulated from the enhancers [4^6]. Recently,
Felsenfeld and Tilghman have proposed a model in which the
unmethylated status of DMR allows the binding of the en-
hancer-blocking activity protein CTCF [20^22]. The presence
of this protein may insulate the Igf2 gene from the enhancer.
Importantly, this factor has been shown to be associated with
a histone deacetylase activity[23]. Hence, this domain provides
a unique model to study the roles of DNA methylation and
histone acetylation in the regulation of gene expression.
To gain further understanding of the relationship between
DNA methylation, histone acetylation and Igf2-H19 gene ex-
pression, we used a chromatin immunoprecipitation (CHIP)
assay to assess the acetylation status associated with normal
and perturbed imprinted activity [24]. By using primary em-
bryonic ¢broblasts derived from normal embryos and em-
bryos containing maternal duplication/paternal de¢ciency of
the imprinted region on distal chromosome 7 (MatDi7), we
evaluated the levels of H4 acetylation across this domain on
both paternal and maternal alleles. These levels were corre-
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lated with the previously reported methylation status of the
corresponding regions. In addition, to assess the functional
role of histone H4 acetylation in the Igf2 and H19 imprinting,
we analysed the e¡ects of an inhibitor of histone deacetylase
both on Igf2 and H19 expression and on the levels of histone
H4 acetylation in this domain. Our study reveals that sites of
allele-speci¢c acetylation are sensitive to trichostatin A (TSA)
treatment and may be involved in the regulation of Igf2 and
H19 at least on the maternal chromosome.
2. Materials and methods
2.1. Cell culture and drug treatment
Cultures of cells derived from normal and MatDi7 embryos have
been generated as described previously [8,25]. Cells were plated in
150 mm dishes at 2U106 cells per plate and cultured in DMEM
(Gibco/BRL) containing 10% (v/v) heat-inactivated foetal calf serum.
After 24 h, 100 ng/ml TSA (Sigma) was added to exponentially grow-
ing cells. Cells were harvested for CHIP assay or for isolation of
nucleic acids after 3 h.
2.2. Antibodies
The preparation and characterisation of polyclonal antisera against
acetylated H4 have been described previously [26]. For the experi-
ments described in this paper, antisera R232/8 (H4Ac8), R252/16
(H4Ac16), R101/12 (H4Ac12) and R41/5 (H4Ac5) were used [24].
2.3. CHIP
Immunoprecipitations were performed using a⁄nity-puri¢ed anti-
sera exactly as described previously [27,28]. DNA was isolated from
antibody-bound (i.e. acetylated) and unbound (i.e. non-acetylated)
chromatin fractions and equal amounts (based on [3H]thymidine
counts) applied to nylon ¢lters by slot-blotting. DNA was hybridised
with 32P-labelled probes corresponding to key areas in the imprinted
domain. Quantitation was performed using a phosphorimager (Mo-
lecular Dynamics) as described previously [27,28].
2.4. Probes
Probes used to scan the Igf2-H19 region were as follows (Fig. 1):
(1) subclone of 5 kb BamHI fragment 3 kb upstream of Igf2 ; (2) 1 kb
HincII exon 2 fragment; (3) 0.9 kb Kpn^BamHI fragment which cov-
ers a part of Igf2-DMR2 region (intron 5^exon 6) [29]; (4) 0.9 kb
intergenic EcoRI/PstI subclone of A4 [30]; (5) 527 bp PCR fragment
encompassing HS1 [9] ; (6) 940 bp PCR fragment which covers the
silencer element; (7) 544 bp PCR fragment which covers the G-repeat;
(8) 0.8 kb fragment of which the 3P end is an EcoRI site at the H19
transcription start site; (9) 1 kb XbaI fragment containing the ¢rst
downstream enhancer.
3. Results
3.1. Histone acetylation level is very variable in the Igf2-H19
domain
To evaluate the levels of histone H4 acetylation across the
Igf2-H19 regions, CHIP assays were performed with a panel
of polyclonal antisera generated against the four di¡erent ace-
tylated lysine residues of histone H4, H4Ac8, H4Ac16,
H4Ac12 and H4Ac5 [24]. Chromatin was prepared by nucle-
ase digestion from normal embryonic ¢broblasts. Nine regions
were analysed (Fig. 1A). Regions 1, 3, 5, 6 and 8 have pre-
viously been shown to be di¡erentially methylated [8,31^33]
and regions 1^6 and 9 contain DNase I hypersensitive sites
[30]. Results for the nine regions tested and the two controls,
L-actin and K-heterochromatin, are shown in Table 1. Levels
of acetylation are presented as the ratio of probes hybridised
to the bound (B, acetylated) and unbound (UB, non-acety-
Fig. 1. A: Schematic of the 100 kb region encompassing Igf2 and H19 analysed in this study, including previously determined areas of DNA
methylation and nuclease hypersensitivity on the two parental chromosomes [8,9,30]. Vertical arrows indicate sites or regions of nuclease hyper-
sensitivity. Horizontal arrows show transcriptional initiation sites. E Active; F inactive. Probes used are indicated by horizontal lines and num-
bered. B: Levels of H4 acetylation at lysines 8 and 16 across the Igf2/H19 domain in embryonic ¢broblasts from normal mice and mice with
two copies of MatDi7. Acetylation levels are expressed as the ratio of hybridisation to DNA from the antibody-bound (B, acetylated) and un-
bound (UB, non-acetylated) fractions for each of the probes indicated in A. Values shown are the average of several independent experiments
and error bars are þ S.E.M. * indicates statistically signi¢cant values.
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lated) fractions measured by slot-blotting followed by quanti-
tative phosphorimaging. The levels of acetylation at L-actin
(B/UB ratio = 1.25) and centric heterochromatin (B/UB ra-
tio = 0.2) for the three antibodies included in Table 1 are as
anticipated from previous results [27]. Antibodies to H4Ac5,
the site that is acetylated least frequently in mature chromatin,
precipitated too little chromatin to allow complete analysis,
though the results that were obtained (not shown) were con-
sistent with those presented in Table 1.
Levels of H4 acetylation in the imprinted domain from
normal (N) cells reveal regional di¡erences along the locus.
The Igf2 locus is characterised by a very high level of acety-
lation at the P2 promoter region (probe 2). The upstream
region (probe 1) exhibits a intermediate level and the down-
stream DMR exhibits a very low acetylation level comparable
to that observed for heterochromatic regions. The intergenic
strongly hypersensitive regions (probe 4) [9,30] show an inter-
mediate level. At the H19 locus, we observed increased acety-
lation at the G-repeat region (probe 7) and even higher levels
at the promoter region (probe 8). In general, the same overall
pattern of acetylation was seen for all four H4 lysines, though
acetylation of lysine 12 was markedly lower than that of 8 and
16 on the Igf2 promoter and higher on the H19 promoter
(Table 1). It is interesting to note that the Igf2 and H19
promoters (probes 2 and 8) exhibit higher levels of acetylation
than have previously been shown for other pol II transcribed
genes [34]. These results suggest that regional di¡erences are
correlated with areas of known regulatory function and im-
plicates histone acetylation in regional control.
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Fig. 2. E¡ect of TSA treatment on Igf2 and H19 expression.
A: Northern blots identifying Igf2, H19 and glyceraldehyde-3-phos-
phate dehydrogenase (Gapdh, control) mRNA extracted from nor-
mal (N) and MatDi7 embryonic ¢broblasts cultivated in presence or
absence of TSA (100 ng/ml). B: Histogram showing the Igf2 and
H19 expression after TSA treatment determined by phosphorimager
analysis of Northern blots. * indicates statistically signi¢cant values.
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3.2. Presence of parental origin-speci¢c di¡erentially acetylated
H4 at the promoter regions of the imprinted genes, Igf2
and H19
To evaluate the level of acetylation on each parental allele,
we compared the level of histone H4 acetylation in primary
embryonic ¢broblasts derived from normal embryos with
those from embryos containing maternal duplication/paternal
de¢ciency of the imprinted region on distal chromosome 7,
where Igf2 and H19 reside (Fig. 1). For all three antibodies,
some areas of known regulatory function (probes 3, 5, 6 and
9) do not show statistically signi¢cant parental origin-speci¢c
di¡erences (Fig. 1B).
Interestingly, levels of H4 acetylation at both lysines 8 and
16 on the Igf2 promoter (probe 2) were 1.6^2.0-fold higher in
normal than in MatDi7 cells, while at the H19 promoter
(probe 5), the MatDi7 cells were 1.3^1.7-fold higher than
normal (Table 1). These di¡erences are statistically signi¢cant.
Thus, the two imprinted promoters show consistent parental
origin-speci¢c acetylation di¡erences, with the active pro-
moters, paternal Igf2 and maternal H19, exhibiting hyperace-
tylation. Consistent di¡erences of this magnitude were not
seen in any of the other regions tested.
3.3. E¡ect of TSA treatment on Igf2 and H19 expression and
on histone H4 acetylation levels across the H19-Igf2
domain
To investigate the role of histone acetylation in the regula-
tion of these two imprinted genes, normal ¢broblasts were
treated for 3 h with an inhibitor of histone deacetylase,
TSA. This treatment allows an overall increase in histone
H4 acetylation in the absence of generalised toxic e¡ects
[35,36]. After 3 h TSA treatment, we did not observe any
Igf2 expression in the MatDi7 cells, suggesting that this treat-
ment is not su⁄cient to induce reactivation of the silent ma-
ternal Igf2 allele (Fig. 2). Strikingly, the H4 acetylation at the
Igf2 promoter region increased signi¢cantly at both lysine 8
and lysine 16 (Fig. 3). This increase can be attributed to the
maternal allele since the same e¡ect was observed in the Mat-
Di7 cells which contain two maternal copies of the distal part
of chromosome 7 (data not shown).
Strikingly and in contrast to what it is generally expected
for a speci¢c histone deacetylase inhibitor, H19 RNA levels
decrease dramatically after TSA treatment. This H19 down-
regulation after TSA treatment was noted previously in a
di¡erent experimental system [37]. This e¡ect can be attrib-
uted to the expressed maternal allele since this down-regula-
tion is also observed in the MatDi7 cells (Fig. 2). However, we
also analysed the regional acetylation associated with this
change in expression. Although no change is evident at re-
gions 5 and 6 (which did not exhibit any regional allele-spe-
ci¢c di¡erences), we observe reproducible reciprocal changes
in the upstream region (Fig. 3). Speci¢cally, signi¢cantly de-
creased acetylation is observed on the H19 promoter (probe 8)
at lysine 8 and in the G-repeat region (probe 7) at the lysine
16. This result is consistent with the decrease in expression of
H19.
4. Discussion
Our systematic regional analysis of the acetylation status
across the Igf2-H19 domain shows that parental origin-specif-
ic acetylation exists at the promoters of the two imprinted
genes. This ¢nding is inconsistent with data from Pedone et
al., who, using CHIP followed by allele-speci¢c PCR, were
unable to detect allele-speci¢c acetylation di¡erences at Igf2
[13]. This di¡erence might be explained by the use of a di¡er-
ent antibody (against tetra-acetylated H4) in their analysis.
Our results indicate that allele-speci¢c hyperacetylation is
highly localised and is concordant with an unmethylated allele
[38].
At the H19 locus, regional acetylation levels are increased
along a domain extending from the G-repeat region to the
promoter. This whole region is highly methylated on the silent
allele and unmethylated on the active allele. However, the
DMR region, believed to be important in the regulation of
Igf2-H19 imprinting, is not di¡erentially acetylated. Only the
promoter is signi¢cantly di¡erentially acetylated. These ¢nd-
ings indicate that di¡erential H4 acetylation is not always
associated with di¡erential methylation. Taken together, the
data for Igf2 and H19 show that allele-speci¢c acetylation
di¡erences can occur in the presence or absence of di¡erential
methylation. Regardless, allelic activity for both genes is as-
sociated with promoter hyperacetylation and hypomethyla-
tion. Furthermore the di¡erences in acetylation levels between
the inactive Igf2 promoter and the inactive H19 promoter
suggest that DNA methylation and hypoacetylation may be
mechanistically linked but such linkage is not required for
gene silencing.
We show that TSA treatment perturbs acetylation levels in
the di¡erentially acetylated domains. Other regions are not
signi¢cantly a¡ected. The acetylation at the P2-Igf2 promoter
region on the maternal chromosome increased 2-fold after
treatment. This was not associated with immediate reactiva-
tion of the maternal allele, although others have shown that
after 24 h, reactivation can occur [13]. Unexpectedly and in
contrast to the Igf2 gene, H19 expression was halved after
TSA treatment. At the H19 promoter, this was associated
with a decrease in the level of Lys8 acetylation and at the
G-repeat a reduction in Lys16 acetylation. Acetylation levels
at other residues tested were not signi¢cantly changed. This
Fig. 3. E¡ect of TSA on histone H4 acetylation across the Igf2-H19
domain. Histogram showing H4 acetylation levels at lysines 16 and
8 expressed as a ratio of values obtained with chromatin from nor-
mal untreated cells or cells grown for 3 h in the presence of TSA.
* indicates statistically signi¢cant values.
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relationship between these two regulatory domains at H19
suggests that lysine residues respond di¡erently to TSA treat-
ment, a ¢nding also reported by Chen and Townes [35]. From
this result, it is not clear whether a decrease in promoter Lys8
acetylation or a decrease in G-repeat Lys16 acetylation is
causally related to the reduction in expression of H19. Neither
change is associated with a change in the methylation state of
the region (data not shown) indicating that acetylation di¡er-
ences alone can a¡ect transcriptional levels at H19.
The upstream region of H19 is an important regulatory
region for controlling imprinting at the Igf2-H19 locus. Ma-
ternally inherited deletions in this region cause reactivation of
the silent Igf2 allele, and a reduction in H19 activity similar to
those we report here. This region has been shown to contain
an insulator element which, when unmethylated on the ma-
ternal chromosome, can bind the CTCF protein which pro-
motes enhancer function at the H19 promoter. On the meth-
ylated paternal allele, the CTCF factor does not bind and the
enhancers are no longer insulated from the Igf2 promoters,
hence Igf2 activity is facilitated on the paternal allele [20^
22,39]. Interestingly, CTCF is associated with a deacetylase
activity that is inhibited in the presence of TSA [23]. Based
on these ¢ndings, it is possible that TSA a¡ects the function
of CTCF on the maternal allele and this is predicted to have a
reciprocal relationship on the expression of Igf2 and H19. The
data are consistent with this; H19 becoming down-regulated
(this report) and Igf2 up-regulated [12,13]. This ¢nding is also
independent of methylation changes that have been suggested
to play a more important role in the regulation of Igf2 activity
and H19 repression on the paternal allele. Hence the situation
on the paternal allele is di¡erent. This is consistent with other
data showing that TSA treatment is not su⁄cient to a¡ect the
activity of the H19 and Igf2 paternal alleles. Thus, although
DNA methylation and histone acetylation both play a role in
Igf2-H19 imprinting, they most likely have distinct functions
on the maternal and paternal chromosomes [13,40].
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